AIBTOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31

AIBOTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026

$0.00+0.00 (+42.86%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Aibotics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Aibotics's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Aibotics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on May 1, 2014
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AIBT.

Revenue growth-100.0% · median -66.3%

Company	Revenue	Growth
PLSH	$2.76M	+50.4%
NTRR	$17.40K	-82.7%
TCRT	$3.00K	-50.0%
AIBT	$0	-100.0%
TCRG	$0	-100.0%
DFTX	–	–

Company

Exchange: OTC
Industry: Medicinal Chemicals & Botanical Products
Fiscal year ends: December 31
Employees: 1
Auditor: Fruci & Associates II, PLLC
SEC CIK: 1763329

Advertisement
300 × 250